The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 346:1871-1877 June 13, 2002 Number 24
NextNext

Intranasal Mupirocin to Prevent Postoperative Staphylococcus aureus Infections
Trish M. Perl, M.D., Joseph J. Cullen, M.D., Richard P. Wenzel, M.D., M. Bridget Zimmerman, Ph.D., Michael A. Pfaller, M.D., Deborah Sheppard, Jennifer Twombley, R.N., Pamela P. French, M.D., M.P.H., Loreen A. Herwaldt, M.D., and the Mupirocin and the Risk of Staphylococcus aureus Study Team

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Editorial
 by Farr, B. M.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Patients with nasal carriage of Staphylococcus aureus have an increased risk of surgical-site infections caused by that organism. Treatment with mupirocin ointment can reduce the rate of nasal carriage and may prevent postoperative S. aureus infections.

Methods We conducted a randomized, double-blind, placebo-controlled trial to determine whether intranasal treatment with mupirocin reduces the rate of S. aureus infections at surgical sites and prevents other nosocomial infections.

Results Of 4030 enrolled patients who underwent general, gynecologic, neurologic, or cardiothoracic surgery, 3864 were included in the intention-to-treat analysis. Overall, 2.3 percent of mupirocin recipients and 2.4 percent of placebo recipients had S. aureus infections at surgical sites. Of the 891 patients (23.1 percent of the 3864 who completed the study) who had S. aureus in their anterior nares, 444 received mupirocin and 447 received placebo. Among the patients with nasal carriage of S. aureus, 4.0 percent of those who received mupirocin had nosocomial S. aureus infections, as compared with 7.7 percent of those who received placebo (odds ratio for infection, 0.49; 95 percent confidence interval, 0.25 to 0.92; P=0.02).

Conclusions Prophylactic intranasal application of mupirocin did not significantly reduce the rate of S. aureus surgical-site infections overall, but it did significantly decrease the rate of all nosocomial S. aureus infections among the patients who were S. aureus carriers.


Source Information

From the University of Iowa Colleges of Medicine and Public Health, Iowa City (T.M.P., J.J.C., R.P.W., M.B.Z., M.A.P., D.S., J.T., L.A.H.); the University of Iowa Hospitals and Clinics, Iowa City (L.A.H.); GlaxoSmithKline, Collegeville, Pa. (P.P.F.); and the Johns Hopkins Medical Institutions, Baltimore (T.M.P.).

Address reprint requests to Dr. Perl at the Johns Hopkins Medical Institutions, Division of Infectious Diseases and Department of Hospital Epidemiology and Infection Control, 425 Osler, Johns Hopkins Hospital, 600 N. Wolfe St., Baltimore, MD 21287.

Full Text of this Article


Related Letters:

Intranasal Mupirocin to Prevent Postoperative Infections
von Eiff C., Kipp F., Becker K., Delgado-Hachmeister J. E., Graviss E. A., Perl T. M., Zimmerman M. B.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:1207-1208, Oct 10, 2002. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.